Company profile
Immuneering Corp
NASDAQ:IMRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Atebimetinib | phase3 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05585320 | phase1_2 | active_not_recruiting | 2022-10-31 | 2026-06-01 | Immuneering Corporation | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors |
| NCT06208124 | phase1_2 | completed | 2024-02-27 | 2025-04-30 | Immuneering Corporation | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors |
| NCT07562152 | phase3 | recruiting | 2026-06-05 | 2028-06-01 | Immuneering Corporation | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
FDA applications (0)
No records yet.